Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Infused chemotherapy use in the elderly after patent expiration.

Conti RM, Rosenthal MB, Polite BN, Bach PB, Shih YC.

Am J Manag Care. 2012 May 1;18(5):e173-8.

2.

Infused chemotherapy use in the elderly after patent expiration.

Conti RM, Rosenthal MB, Polite BN, Bach PB, Shih YC.

J Oncol Pract. 2012 May;8(3 Suppl):e18s-23s. doi: 10.1200/JOP.2012.000541.

3.
4.

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.

Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):953-64. doi: 10.1007/s00280-013-2272-0.

PMID:
23982118
5.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

6.

Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.

Lopes Gde L.

Ann Oncol. 2013 Sep;24 Suppl 5:v13-6. doi: 10.1093/annonc/mdt323.

PMID:
23975699
7.

Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.

Zhao Z, Pelletier E, Barber B, Bhosle M, Wang S, Gao S, Klingman D.

Curr Med Res Opin. 2012 Feb;28(2):221-9. doi: 10.1185/03007995.2011.650503.

PMID:
22171947
8.

Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.

Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH.

Mol Oncol. 2014 Feb;8(1):59-67. doi: 10.1016/j.molonc.2013.09.001.

9.

Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.

Jansman FG, Idzinga FS, Smit WM, de Graaf JC, Coenen JL, Sleijfer DT, Brouwers JR.

Clin Ther. 2005 Mar;27(3):327-35.

PMID:
15878386
10.

Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.

Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS.

J Natl Cancer Inst. 2014 Feb;106(2):djt371. doi: 10.1093/jnci/djt371.

PMID:
24511107
11.

Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ.

J Natl Cancer Inst. 2009 Oct 21;101(20):1412-22. doi: 10.1093/jnci/djp319.

12.

Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.

Cortejoso L, García MI, García-Alfonso P, González-Haba E, Escolar F, Sanjurjo M, López-Fernández LA.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1463-72. doi: 10.1007/s00280-013-2145-6. Erratum in: Cancer Chemother Pharmacol. 2013 Aug;72(2):491.

PMID:
23543295
13.
14.

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.

Aparicio T, Desramé J, Lecomte T, Mitry E, Belloc J, Etienney I, Montembault S, Vayre L, Locher C, Ezenfis J, Artru P, Mabro M, Dominguez S; AGEO..

Br J Cancer. 2003 Oct 20;89(8):1439-44.

15.

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.

Petrioli R, Sabatino M, Fiaschi AI, Marsili S, Pozzessere D, Messinese S, Correale P, Civitelli S, Tanzini G, Tani F, De Martino A, Marzocca G, Lorenzi M, Giorgi G, Francini G.

Br J Cancer. 2004 Jan 26;90(2):306-9.

16.
17.

Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.

Varol U, Karaca B, Cakar B, Sezgin C, Karabulut B, Uslu R.

Am J Clin Oncol. 2013 Aug;36(4):388-91. doi: 10.1097/COC.0b013e318248da7c.

PMID:
22643568
18.

Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.

Landsman-Blumberg PB, Carter GC, Johnson BH, Sedgley R, Nicol SJ, Li L, Shankaran V.

Clin Colorectal Cancer. 2014 Sep;13(3):178-84. doi: 10.1016/j.clcc.2014.05.001.

PMID:
25065655
19.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

García-Foncillas J, Díaz-Rubio E.

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Review.

PMID:
20709651
20.

Supplemental Content

Support Center